Category: Patient Advocacy

All Podcast Categories
S4-20.1 - Who is going to be the Larry Kramer of NASH?

S4-20.1 – Who is going to be the Larry Kramer of NASH?

In an honest discussion with Donna Cryer, Surfing NASH explores the challenges of championing patient-centricity and the importance of allied health as many impending and important decisions come to a head for the NAFLD/NASH community. This introductory conversation features an impactful statement from Donna on the gravity surrounding these milestone moments and why patient inputs should be held paramount.

S4-20 - Leveraging Patient Voice and Needs in the NASH Community

S4-20 – Leveraging Patient Voice and Needs in the NASH Community

In an honest discussion with Donna Cryer, Surfing NASH explores the challenges of championing patient-centricity and the importance of allied health as many impending and important decisions come to a head for the NAFLD/NASH community. Among other topics, the panelists comment on the recent draft report from ICER, the landscape of nomenclature consensus and, generally, how to absorb different perspectives into a common discussion while giving each the weight that they deserve.

S4-19.5 - Teasing the Difference Between Patient Advocate Voice and Patient Advocate Vote

S4-19.5 – Teasing the Difference Between Patient Advocate Voice and Patient Advocate Vote

Patient advocates and friends of the podcast Mike Betel (Fatty Liver Alliance), Tony Villiotti (NASHkNOWledge) and Wayne Eskridge (Fatty Liver Foundation) join co-hosts Louise Campbell and Roger Green to share a range of impressions on a public comments session around the draft report released by the Institute for Clinical and Economic Review (ICER) on resmetirom and obeticholic acid for NASH. In this final conversation, each describes the most important thing they would like ICER to learn before another NASH drug analysis.

S4-19.4 - Patient Advocates Describe the Reasoning Behind Their Testimonies

S4-19.4 – Patient Advocates Describe the Reasoning Behind Their Testimonies

Patient advocates and friends of the podcast Mike Betel (Fatty Liver Alliance), Tony Villiotti (NASHkNOWledge) and Wayne Eskridge (Fatty Liver Foundation) join co-hosts Louise Campbell and Roger Green to share a range of impressions on a public comments session around the draft report released by the Institute for Clinical and Economic Review (ICER) on resmetirom and obeticholic acid for NASH. In this conversation, the panelists dive into why they shared their specific testimonies among other takeaways.

S4-19.3 - The Role of Biopsy in Prescribing NASH Therapeutics

S4-19.3 – The Role of Biopsy in Prescribing NASH Therapeutics

Patient advocates and friends of the podcast Mike Betel (Fatty Liver Alliance), Tony Villiotti (NASHkNOWledge) and Wayne Eskridge (Fatty Liver Foundation) join co-hosts Louise Campbell and Roger Green to share a range of impressions on a public comments session around the draft report released by the Institute for Clinical and Economic Review (ICER) on resmetirom and obeticholic acid for NASH. In this conversation, the group discusses the role of biopsy, drug trial endpoints and more.

S4-19.2 - Patient Advocates React to the Word “Empathy”

S4-19.2 – Patient Advocates React to the Word “Empathy”

Patient advocates and friends of the podcast Mike Betel (Fatty Liver Alliance), Tony Villiotti (NASHkNOWledge) and Wayne Eskridge (Fatty Liver Foundation) join co-hosts Louise Campbell and Roger Green to share a range of impressions on a public comments session around the draft report released by the Institute for Clinical and Economic Review (ICER) on resmetirom and obeticholic acid for NASH.

S4-19.1 - How Did the Patient Advocates Come to Offer Testimonies?

S4-19.1 – How Did the Patient Advocates Come to Offer Testimonies?

Patient advocates and friends of the podcast Mike Betel (Fatty Liver Alliance), Tony Villiotti (NASHkNOWledge) and Wayne Eskridge (Fatty Liver Foundation) join co-hosts Louise Campbell and Roger Green to share a range of impressions on a public comments session around the draft report released by the Institute for Clinical and Economic Review (ICER) on resmetirom and obeticholic acid for NASH. This opening conversation reveals how each guest became involved in the process and offers a preview of their reactions to the experience.

S4-17.8 - Predictions for the Surfing NASH 6th Anniversary Special

S4-17.8 – Predictions for the Surfing NASH 6th Anniversary Special

The Surfing NASH 3rd Anniversary Special offers a look back at the history of the podcast and the future of Fatty Liver with the original ‘Big Band’ of Surfers Stephen Harrison, Jörn Schattenberg, Louise Campbell and Roger Green. In this final conversation the group summarizes their thoughts and suggests what will be discussed on the 6th Anniversary Special in 2026. At the end of the episode, there is a birthday surprise.

S4-17.7 - Discussing the Drug Development Landscape and Growing Community Education

S4-17.7 – Discussing the Drug Development Landscape and Growing Community Education

The Surfing NASH 3rd Anniversary Special offers a look back at the history of the podcast and the future of Fatty Liver with the original ‘Big Band’ of Surfers Stephen Harrison, Jörn Schattenberg, Louise Campbell and Roger Green. In this conversation the group continues to discuss the trajectory of liver science, drug development, driving education, clinical trials and more.

S4-17.6 - The Trajectory of Liver Science: How Far Have We Come?

S4-17.6 – The Trajectory of Liver Science: How Far Have We Come?

The Surfing NASH 3rd Anniversary Special offers a look back at the history of the podcast and the future of Fatty Liver with the original ‘Big Band’ of Surfers Stephen Harrison, Jörn Schattenberg, Louise Campbell and Roger Green. In this conversation the group dives into the tremendous progress being made in liver science and ultimately building a roadmap to therapy.

Sponsoring Partnerships

Sponsoring partnerships with SurfingMASH present a multifaceted avenue for companies seeking to amplify their brand presence and engage with targeted audiences.